glp 1 and alzheimer's study Frontiers Can popular diabetes and weight-loss

Ferreira LSS, Fernandes CS, Vieira MNN, De, Felice FG

Choose your medication (compounded semaglutide or Zepbound)

Patients typically notice initial improvements as early as four weeks post-treatment, with ongoing benefits developing over three to six months

Silymarin also has shown benefit in patients with Alzheimer's disease, Parkinson's disease, and cerebral ischemia

Wegovy's additional FDA approval is for cardiovascular risk reduction (reducing heart attack and stroke risk), granted in March 2024

In 2014, Saxenda became the first GLP-1 analog approved for weight loss, and in 2021, semaglutide (Wegovy), became the second GLP-1 analog to receive this indication